<DOC>
	<DOCNO>NCT01467479</DOCNO>
	<brief_summary>The purpose study treat human immunodeficiency virus ( HIV ) Hepatitis C Virus ( HCV ) co-infected subject telaprevir , pegylated interferon alfa-2a ( Peg-IFN-alfa-2a ) , ribavirin ( RBV ) achieve undetectable hepatitis C virus ribonucleic acid ( HCV RNA ) 12 week last plan dose study drug .</brief_summary>
	<brief_title>A Study Treat Subjects With Telaprevir , Ribavirin , Peginterferon Who Are Coinfected With HIV Hepatitis C Virus ( HCV )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Participants must chronic , genotype 1a 1b , hepatitis C HCV RNA great ( &gt; ) 1000 international unit per milliliter ( IU/mL ) Population A : HCV Pegylated interferon ( PegIFN ) /RBV treatment naive ( receive prior HCV therapy ) PegIFN/RBV prior treatment relapse Population B : PegIFN/RBV prior null partial responder Participants must achieve undetectable HCV RNA 24 week last plan dose study drug ( SVR24 ) least 1 prior course Peg IFN/RBV therapy standard duration Participant must positive HIV antibody Screening Participant must diagnosis HIV1 infection &gt; 6 month Screening Participants take 1 follow permissible highly active antiretroviral therapy ( HAART ) regimens HIV continuously 12 week prior screen : Atripla® equivalent component ( efavirenz , tenofovir , emtricitabine ) Efavirenz plus Epzicom® ( abacavir , lamivudine ) equivalent component Boosted atazanavir ( atazanavir ritonavir ) plus Truvada® ( tenofovir , emtricitabine ) equivalent component Boosted atazanavir plus Epzicom® , equivalent component Raltegravir plus Truvada® , equivalent component Raltegravir plus Epzicom® , equivalent component Cluster differentiation 4 ( CD4 ) count human immunodeficiency virus Type 1 ( HIV1 ) ribonucleic acid ( RNA ) meeting acceptable criterion Screening specify protocol Laboratory value within acceptable range Screening specify protocol Subjects anticipate need switch HAART regimen within 14 week Day 1 switch occur 12 week prior Day 1 Use azidothymidine ( AZT ) , didanosine ( ddI ) stavudine ( d4T ) nucleoside Contraindications plan HAART component per respective drug label information Contraindications PegIFN RBV Evidence hepatic decompensation Clinical suspicion acute hepatitis Any cause liver disease addition hepatitis C History organ transplantation ( except cornea skin ) Autoimmunemediated disease Participated investigational drug study within 90 day Day 1 Previous treatment HCV protease inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>